American National Bank Makes New $113,000 Investment in Solventum Co. (NYSE:SOLV)

American National Bank purchased a new stake in shares of Solventum Co. (NYSE:SOLV) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 2,145 shares of the company’s stock, valued at approximately $113,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SOLV. EverSource Wealth Advisors LLC bought a new stake in shares of Solventum during the 1st quarter valued at about $30,000. Partnership Wealth Management LLC purchased a new stake in Solventum in the second quarter valued at approximately $26,000. CarsonAllaria Wealth Management Ltd. bought a new stake in Solventum during the second quarter valued at approximately $27,000. M&R Capital Management Inc. purchased a new position in Solventum in the 2nd quarter worth approximately $27,000. Finally, Beach Investment Counsel Inc. PA bought a new position in shares of Solventum in the 2nd quarter worth $27,000.

Solventum Stock Up 0.2 %

Shares of SOLV traded up $0.10 during trading hours on Thursday, hitting $59.76. The company had a trading volume of 511,222 shares, compared to its average volume of 2,076,608. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90. The company’s 50 day moving average is $54.54.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, August 8th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.10. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts expect that Solventum Co. will post 6.4 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on SOLV. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. Argus initiated coverage on Solventum in a research note on Monday, June 24th. They set a “hold” rating for the company. Bank of America cut their price objective on Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a report on Tuesday, June 25th. The Goldman Sachs Group raised their price objective on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Finally, Morgan Stanley dropped their target price on Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $58.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.